Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: Synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7502-7515

  Hochdörffer, Katrin ^a   Abu Ajaj, Khalid ^a,c   Schäfer Obodozie, Cynthia ^b   Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b PROQINASE GMBH   (Germany)

^c LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN B; DOXORUBICIN; HYDROXYAPATITE;

ARTICLE; BONE MATRIX; BONE METASTASIS; CONTROLLED STUDY; DRUG BINDING; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PH;

BONE AND BONES; BONE NEOPLASMS; CATHEPSIN B; DIPHOSPHONATES; DOXORUBICIN; DURAPATITE; HUMANS; HYDROGEN-ION CONCENTRATION; PRODRUGS;

EID: 84866334630     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300493m     Document Type: Article

References (61)

1. Hong, W. K.; Bast, R. C.; Hait, W.; Kufe, D. W.; Holland, J. F. Holland-Frei Cancer Medicine; 8th ed.; BC Decker: Shelton, CT, 2010.
2. Rubens, R. D. Bone metastases-the clinical problem Eur. J. Cancer 1998, 34, 210-213
3. Coleman, R. E. Skeletal complications of malignancy Cancer 1997, 80, 1588-1594 (Pubitemid 27444031)
4. Rubens, R. D. Metastatic breast cancer Curr. Opin. Oncol. 1995, 7, 523-526
5. Fleisch, H. Bisphosphonates in bone disease: from the laboratory to the patient; 3rd ed.; The Parthenon Publishing Group: London, 1997.
6. Lin, J. H. Bisphosphonates: a review of their pharmacokinetic properties Bone 1996, 18, 75-85 (Pubitemid 26092586)
7. Bartl, R.; von Treschkow, E.; Bartl, C. Bisphosphonat-Manual: Wirkungen-Indikationen-Strategien; Springer-Verlag: Berlin-Heidelberg, 2006.
8. Goeckeler, W. F.; Edwards, B.; Volkert, W. A.; Holmes, R. A.; Simon, J. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents J. Nucl. Med. 1987, 28, 495-504 (Pubitemid 17074172)
9. Bayouth, J. E.; Macey, D. J.; Kasi, L. P.; Fossella, F. V. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases J. Nucl. Med. 1994, 35, 63-69 (Pubitemid 24018442)
10. Hirabayashi, H.; Sawamoto, T.; Fujisaki, J.; Tokunaga, Y.; Kimura, S. Relationship between physicochemical and osteotropic properties of bisphosphonic derivatives: rational design for osteotropic drug delivery system (ODDS) Pharm. Res. 2001, 18, 646-651 (Pubitemid 32595793)
11. Wingen, F.; Eichmann, T.; Manegold, C.; Krempien, B. Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat J. Cancer Res. Clin. Oncol. 1986, 111, 35-41 (Pubitemid 16161965)
12. Wingen, F.; Sterz, H.; Blum, H.; Moller, H.; Pittermann, W. Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino] phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma J. Cancer Res. Clin. Oncol. 1986, 111, 209-219 (Pubitemid 16093081)
13. Wingen, F.; Pool, B. L.; Klein, P.; Klenner, T.; Schmahl, D. Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat-benefit of combining bisphosphonates with cytostatic agents Invest. New Drugs 1988, 6, 155-167
14. Pool, B. L.; Berger, M.; Schlehofer, J. R.; Wingen, F. In vivo and in vitro investigations on biological effects of aromatic bis-(2-chloroethyl)amino- bisphosphonic acids, new agents proposed for chemotherapy of bone tumors: cytostatic activity in rat osteosarcoma; toxicity and genotoxicity in liver and bone marrow; mutagenicity in S. typhimurium Invest. New Drugs 1988, 6, 67-78
15. Klenner, T.; Valenzuela-Paz, P.; Keppler, B. K.; Angres, G.; Scherf, H. R. Cisplatin-linked phosphonates in the treatment of the transplantable osteosarcoma in vitro and in vivo Cancer Treat. Rev. 1990, 17, 253-259
16. Klenner, T.; Wingen, F.; Keppler, B. K.; Krempien, B.; Schmahl, D. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J. Cancer Res. Clin. Oncol. 1990, 116, 341-350 (Pubitemid 20296353)
17. Sturtz, G. L.; Appere, G.; Breistol, K.; Fodstad, O.; Schwartsmann, G. Eur. J. Med. Chem. 1992, 27, 825-833
18. Sturtz, G. L.; Couthon, H. M.; Fabulet, O.; Mian, M.; Rosini, S. Synthesis of gem -bisphosphonic methotrexate conjugates and their biological response towards Walker's osteosarcoma Eur. J. Med. Chem. 1993, 28, 899-903 (Pubitemid 23347722)
19. Hosain, F.; Spencer, R. P.; Couthon, H. M.; Sturtz, G. L. Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem -bisphosphonate conjugate of methotrexate J. Nucl. Med. 1996, 37, 105-107 (Pubitemid 26123435)
20. Fabulet, O.; Sturtz, G. L. Synthesis of gem -bisphosphonic doxorubicin conjugates Phosphorus, Sulfur Silicon Relat. Elem. 1995, 101, 225-234
21. El-Mabhouh, A. A.; Angelov, C. A.; Cavell, R.; Mercer, J. R. A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer Nucl. Med. Biol. 2006, 33, 715-722 (Pubitemid 44247739)
22. El-Mabhouh, A. A.; Mercer, J. R. 188Re-labelled gemcitabine/ bisphosphonate (Gem/BP): a multifunctional, bone-specific agent as a potential treatment for bone metastases Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1240-1248
23. El-Mabhouh, A. A.; Nation, P. N.; Abele, J. T.; Riauka, T.; Postema, E. A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases Oncol. Res. 2011, 19, 287-295
24. Erez, R.; Ebner, S.; Attali, B.; Shabat, D. Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation Bioorg. Med. Chem. Lett. 2008, 18, 816-820
25. Miller, K.; Eldar-Boock, A.; Polyak, D.; Segal, E.; Benayoun, L. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model Mol. Pharmaceutics 2011, 8, 1052-1062
26. Segal, E.; Pan, H.; Benayoun, L.; Kopeckova, P.; Shaked, Y. Enhanced antitumor activity and safety profile of targeted nanoscaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances Biomaterials 2011, 32, 4450-4463
27. Miller, K.; Erez, R.; Segal, E.; Shabat, D.; Satchi-Fainaro, R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate Angew. Chem., Int. Ed. Engl. 2009, 48, 2949-2954
28. Pan, H.; Sima, M.; Kopeckova, P.; Wu, K.; Gao, S. Biodistribution and pharmacokinetic studies of bone-targeting N -(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates Mol. Pharmaceutics 2008, 5, 548-558
29. Blair, H. C.; Teitelbaum, S. L.; Ghiselli, R.; Gluck, S. Osteoclastic bone resorption by a polarized vacuolar proton pump Science 1989, 245, 855-857 (Pubitemid 19223662)
30. Palokangas, H.; Mulari, M.; Vaananen, H. K. Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts J. Cell Sci. 1997, 110 (Pt 15) 1767-1780 (Pubitemid 27352856)
31. Baron, R.; Neff, L.; Louvard, D.; Courtoy, P. J. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100 kD lysosomal membrane protein at the osteoclast ruffled border J. Cell Biol. 1985, 101, 2210-2222 (Pubitemid 16169951)
32. Kingsley, L. A.; Fournier, P. G.; Chirgwin, J. M.; Guise, T. A. Molecular biology of bone metastasis Mol. Cancer Ther. 2007, 6, 2609-2617 (Pubitemid 350058141)
33. Teitelbaum, S. L. Bone resorption by osteoclasts Science 2000, 289, 1504-1508
34. Arnett, T. Regulation of bone cell function by acid-base balance Proc. Nutr. Soc. 2003, 62, 511-520 (Pubitemid 36841626)
35. Miyake, H.; Hara, I.; Yamanaka, K.; Arakawa, S.; Kamidono, S. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer Int. J. Oncol. 1999, 14, 535-541
36. Woodward, J. K. L.; Holen, I.; Coleman, R. E.; Buttle, D. J. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer Bone 2007, 41, 912-927 (Pubitemid 350116741)
37. Cher, M. L.; Biliran, H. R., Jr.; Bhagat, S.; Meng, Y.; Che, M. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 7847-7852 (Pubitemid 36760058)
38. Podgorski, I.; Linebaugh, B. E.; Sameni, M.; Jedeszko, C.; Bhagat, S. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer Neoplasia 2005, 7, 207-223 (Pubitemid 40411633)
39. Littlewood-Evans, A. J.; Bilbe, G.; Bowler, W. B.; Farley, D.; Wlodarski, B. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma Cancer Res. 1997, 57, 5386-5390 (Pubitemid 27516378)
40. Brubaker, K. D.; Vessella, R. L.; True, L. D.; Thomas, R.; Corey, E. Cathepsin K mRNA and protein expression in prostate cancer progression J. Bone Miner. Res. 2003, 18, 222-230 (Pubitemid 36125914)
41. Kratz, F.; Muller-Driver, R.; Hofmann, I.; Drevs, J.; Unger, C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy J. Med. Chem. 2000, 43, 1253-1256 (Pubitemid 30212566)
42. Kratz, F.; Warnecke, A.; Scheuermann, K.; Stockmar, C.; Schwab, J. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound J. Med. Chem. 2002, 45, 5523-5533 (Pubitemid 35424970)
43. Kratz, F.; Mansour, A.; Soltau, J.; Warnecke, A.; Fichtner, I. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen Arch. Pharm. (Weinheim) 2005, 338, 462-472 (Pubitemid 41564256)
44. Chung, D.-E.; Kratz, F. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type plasminogen activator (uPA) Bioorg. Med. Chem. Lett. 2006, 16, 5157-5163 (Pubitemid 44247692)
45. Schmid, B.; Chung, D.-E.; Warnecke, A.; Fichtner, I.; Kratz, F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy Bioconjugate Chem. 2007, 18, 702-716 (Pubitemid 47010789)
46. Kratz, F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials Expert Opin. Invest. Drugs 2007, 16, 855-866 (Pubitemid 46882358)
47. Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 2008, 132, 171-183
48. Gianni, L.; Grasselli, G.; Cresta, S.; Locatelli, A.; Vigano, L. Anthracyclines Cancer Chemother. Biol. Response Modif. 2002, 20, 59-69
49. Kratz, F.; Warnecke, A.; Schmid, B.; Chung, D. E.; Gitzel, M. Prodrugs of anthracyclines in cancer chemotherapy Curr. Med. Chem. 2006, 13, 477-523
50. Abu Ajaj, K.; Graeser, R.; Fichtner, I.; Kratz, F. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B Cancer Chemother. Pharmacol. 2009, 64, 413-418
51. Bansal, G.; Wright, J. E. I.; Zhang, S.; Zernicke, R. F.; Uludag, H. Imparting mineral affinity to proteins with thiol-labile disulfide linkages J. Biomed. Mater. Res., Part A 2005, 74, 618-628 (Pubitemid 41216264)
52. Woodward, J. K.; Holen, I.; Coleman, R. E.; Buttle, D. J. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer Bone 2007, 41, 912-927 (Pubitemid 350116741)
53. Webb, S. D.; Sherratt, J. A.; Fish, R. G. Alterations in proteolytic activity at low pH and its association with invasion: a theoretical model Clin. Exp. Metastasis 1999, 17, 397-407 (Pubitemid 30019997)
54. Arkona, C.; Wiederanders, B. Expression, subcellular distribution and plasma membrane binding of cathepsin B and gelatinases in bone metastatic tissue Biol. Chem. 1996, 377, 695-702 (Pubitemid 26418094)
55. Dubowchik, G. M.; Firestone, R. A.; Padilla, L.; Willner, D.; Hofstead, S. J. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity Bioconjugate Chem. 2002, 13, 855-869 (Pubitemid 34801129)
56. Peterson, J. J.; Meares, C. F. Cathepsin substrates as cleavable peptide linkers in bioconjugates, selected from a fluorescence quench combinatorial library Bioconjugate Chem. 1998, 9, 618-626
57. Barrett, A. J.; Kirschke, H. Cathepsin B, cathepsin H, and cathepsin L Methods Enzymol. 1981, 80 (Pt C) 535-561
58. Swanson, A. A.; Martin, B. J.; Spicer, S. S. Human placental cathepsin B1. Isolation and some physical properties Biochem. J. 1974, 137, 223-228
59. Fleisch, H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease Drugs 1991, 42, 919-944 (Pubitemid 21920790)
60. Abu Ajaj, K.; Biniossek, M. L.; Kratz, F. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs Bioconjugate Chem. 2009, 20, 390-396
61. Ellman, G. L. Tissue sulfhydryl groups Arch. Biochem. Biophys. 1959, 82, 70-77